Insulin Antibody Monoclonal (Human)

Description

Human Insulin Antibody

References

• Insulin’s direct hepatic effect explains the inhibition of glucose production caused by insulin secretion. Edgerton DS, Kraft G, Smith M, Farmer B, Williams PE, Coate KC, Printz RL, O’Brien RM, Cherrington AD. JCI Insight. 2017 Mar 23;2(6):e91863.
• Characterisation of insulin analogues therapeutically available to patients. Adams GG, Meal A, Morgan PS, Alzahrani QE, Zobel H, Lithgo R, Kok MS, Besong DTM, Jiwani SI, Ballance S, Harding SE, Chayen N, Gillis RB. PLoS One. 2018 Mar 29;13(3):e0195010.
• Identification of recombinant human insulin and biosynthetic insulin analogues by multiplexed targeted unlabeled mass spectrometry of proteotypic tryptic peptides. Qasem RJ, Aldawsari AS, Almutairi FE, Alsadoon AS. J Pharm Biomed Anal. 2019 Aug 5;172:357-363.
• Insulin–carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Call R, Grimsley M, Cadwallader L, Cialone L, Hill M, Hreish V, King ST, Riche DM. Postgrad Med. 2010 May;122(3):158-65.
• [Assessing nurses’ knowledge of insulin administration and the impact of the introduction of concentrated insulins.]. Leroy V, Lazaro M, Raymond B, Henry A. Rech Soins Infirm. 2018 Sep;(134):44-51.
• Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus. Dunn CJ, Plosker GL. Pharmacoeconomics. 2002;20(14):989-1025.
• Validation of a Fully Automated Immunoaffinity Workflow for the Detection and Quantification of Insulin Analogs by LC-MS-MS in Postmortem Vitreous Humor. Legg KM, Labay LM, Aiken SS, Logan BK. J Anal Toxicol. 2019 Aug 23;43(7):505-511.
• Strategy for peptide quantification using LC-MS in regulated bioanalysis: case study with a glucose-responsive insulin. Xu Y, Goykhman D, Wang M, Jackson T, Xie I, Willson K, Breidinger S, Schuck H, Harrelson J, Woolf EJ. Bioanalysis. 2018 Aug 1;10(15):1207-1220.